The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s ...
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking ...
Physician-scientists from Rutgers Cancer Institute and RWJBarnabas Health will present practice-changing research and emerging treatment approaches across a range of cancer types at the 2026 American ...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO ...
Zacks Investment Research on MSN
EXEL collaborates with MRK for late-stage colorectal cancer study
Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline ...
The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results